Literature DB >> 30918867

The interaction of dyslipidaemia with glycaemia in an adult population study.

Sarah Cuschieri1, Josanne Vassallo2, Neville Calleja3,4, Christopher Barbara5, Julian Mamo2.   

Abstract

PURPOSE: Individuals with dysglycaemic are prone to dyslipidaemia. Understanding the dyslipidaemic status of dysglycaemic individuals is essential for monitoring and early prevention. The aim was to assess the control of lipidaemia by glycaemic status in a representative adult population.
METHODS: A retrospective health examination survey was performed on a sample of adults (n = 3947) in Malta in 2014-6. Sociodemographic data, biochemistry blood tests and anthropometric measurements were gathered. Statistical analysis was performed to evaluate the lipidaemic status and its control across the glycaemic spectrum (normoglycemic, impaired fasting glucose individuals, new diabetics and known diabetics).
RESULTS: The prevalence of uncontrolled dyslipidaemia was 7.75% (CI 95%: 6.69-8.63), among whom 6.97% (CI 95%: 6.21-7.81) were naïve dyslipidaemic. A progressive elevation in both LDL-C and total cholesterol but not triglycerides was present among uncontrolled dyslipidaemia individuals across the glycaemic spectrum. Global dyslipidaemia was present in 19.26% (CI 95%: 18.05-20.52) of the total general population and in 46.59% (CI 95%: 40.49-52.69%) of known diabetics. Most individuals irrespective of lipid status were normoglycaemic.
CONCLUSIONS: Dyslipidaemia occurs in the presence of insulin resistance. Dyslipidaemia predominated in the normoglycaemic state irrespective of statins use, indicating the need to manage dyslipidaemia prior to dysglycaemia.

Entities:  

Keywords:  Diabetes mellitus, type 2; Epidemiology; Hyperlipidaemia; Insulin resistance, policy; Malta

Year:  2018        PMID: 30918867      PMCID: PMC6405403          DOI: 10.1007/s40200-018-0377-z

Source DB:  PubMed          Journal:  J Diabetes Metab Disord        ISSN: 2251-6581


  32 in total

Review 1.  Clinical review 124: Diabetic dyslipidemia: causes and consequences.

Authors:  I J Goldberg
Journal:  J Clin Endocrinol Metab       Date:  2001-03       Impact factor: 5.958

Review 2.  2. Classification and Diagnosis of Diabetes.

Authors: 
Journal:  Diabetes Care       Date:  2016-01       Impact factor: 19.112

Review 3.  Factors associated with gender differences in medication adherence: a longitudinal study.

Authors:  Shiah-Lian Chen; Wen-Lieng Lee; Tienli Liang; I-Chen Liao
Journal:  J Adv Nurs       Date:  2014-02-10       Impact factor: 3.187

Review 4.  Diabetic dyslipidaemia.

Authors:  D J Betteridge
Journal:  Eur J Clin Invest       Date:  1999-06       Impact factor: 4.686

Review 5.  Dyslipidemia in type 2 diabetes: prevalence, pathophysiology, and management.

Authors:  Joe M Chehade; Margaret Gladysz; Arshag D Mooradian
Journal:  Drugs       Date:  2013-03       Impact factor: 9.546

Review 6.  Lipid and lipoprotein dysregulation in insulin resistant states.

Authors:  Rita Kohen Avramoglu; Heather Basciano; Khosrow Adeli
Journal:  Clin Chim Acta       Date:  2006-02-09       Impact factor: 3.786

7.  Characterization of lipid parameters in diabetic and non-diabetic atherosclerotic patients.

Authors:  Fatima Ali; Hassan Jamil; Sanam Saiqa Anwar; Nadia Wajid
Journal:  J Geriatr Cardiol       Date:  2015-01       Impact factor: 3.327

8.  The diabesity health economic crisis-the size of the crisis in a European island state following a cross-sectional study.

Authors:  Sarah Cuschieri; Josanne Vassallo; Neville Calleja; Nikolai Pace; Janice Abela; Bader A Ali; Fatemah Abdullah; Elizier Zahra; Julian Mamo
Journal:  Arch Public Health       Date:  2016-12-12

9.  The Effects of Socioeconomic Determinants on Hypertension in a Cardiometabolic At-Risk European Country.

Authors:  Sarah Cuschieri; Josanne Vassallo; Neville Calleja; Nikolai Pace; Julian Mamo
Journal:  Int J Hypertens       Date:  2017-08-28       Impact factor: 2.420

10.  Healthy people and healthy profits? Elaborating a conceptual framework for governing the commercial determinants of non-communicable diseases and identifying options for reducing risk exposure.

Authors:  Kent Buse; Sonja Tanaka; Sarah Hawkes
Journal:  Global Health       Date:  2017-06-15       Impact factor: 4.185

View more
  2 in total

1.  COVID-19 panic, solidarity and equity-the Malta exemplary experience.

Authors:  Sarah Cuschieri
Journal:  Z Gesundh Wiss       Date:  2020-05-30

2.  Insight into the Occurrence of Common Non-communicable Diseases at a Population Level and the Potential Impact During the Coronavirus Pandemic - a Need for a Syndemic Healthcare Approach?

Authors:  Sarah Cuschieri; Stephan Grech
Journal:  SN Compr Clin Med       Date:  2021-09-22
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.